199 related articles for article (PubMed ID: 34530257)
1. PD-L1 evaluation in head and neck squamous cell carcinoma: Insights regarding specimens, heterogeneity and therapy.
Paolino G; Pantanowitz L; Barresi V; Pagni F; Munari E; Moretta L; Brunelli M; Bariani E; Vigliar E; Pisapia P; Malapelle U; Troncone G; Girolami I; Eccher A
Pathol Res Pract; 2021 Oct; 226():153605. PubMed ID: 34530257
[TBL] [Abstract][Full Text] [Related]
2. Considerable interlaboratory variation in PD-L1 positivity for head and neck squamous cell carcinoma in the Netherlands- A nationwide evaluation study.
Hempenius MA; Koomen BM; Deckers IAG; Oosting SF; Willems SM; van der Vegt B
Histopathology; 2024 Jul; 85(1):133-142. PubMed ID: 38606992
[TBL] [Abstract][Full Text] [Related]
3. Reproducibility of PD-L1 immunohistochemistry interpretation across various types of genitourinary and head/neck carcinomas, antibody clones, and tissue types.
Wang C; Hahn E; Slodkowska E; Eskander A; Enepekides D; Higgins K; Vesprini D; Liu SK; Downes MR; Xu B
Hum Pathol; 2018 Dec; 82():131-139. PubMed ID: 30075156
[TBL] [Abstract][Full Text] [Related]
4. Development of a programmed cell death ligand-1 immunohistochemical assay validated for analysis of non-small cell lung cancer and head and neck squamous cell carcinoma.
Rebelatto MC; Midha A; Mistry A; Sabalos C; Schechter N; Li X; Jin X; Steele KE; Robbins PB; Blake-Haskins JA; Walker J
Diagn Pathol; 2016 Oct; 11(1):95. PubMed ID: 27717372
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of programmed death ligand 1 expression in cytology to determine eligibility for immune checkpoint inhibitor therapy in patients with head and neck squamous cell carcinoma.
Liu Z; Williams M; Stewart J; Glisson BS; Fuller C; Roy-Chowdhuri S
Cancer Cytopathol; 2022 Feb; 130(2):110-119. PubMed ID: 34375025
[TBL] [Abstract][Full Text] [Related]
6. Spatial Intratumoral Heterogeneity Expression of PD-L1 Antigen in Head and Neck Squamous Cell Carcinoma.
Hirshoren N; Al-Kharouf I; Weinberger JM; Eliashar R; Popovtzer A; Knaanie A; Fellig Y; Neuman T; Meir K; Maly A; Vainer GW
Oncology; 2021; 99(7):464-470. PubMed ID: 33789303
[TBL] [Abstract][Full Text] [Related]
7. Comparison of three PD-L1 immunohistochemical assays in head and neck squamous cell carcinoma (HNSCC).
de Ruiter EJ; Mulder FJ; Koomen BM; Speel EJ; van den Hout MFCM; de Roest RH; Bloemena E; Devriese LA; Willems SM
Mod Pathol; 2021 Jun; 34(6):1125-1132. PubMed ID: 32759978
[TBL] [Abstract][Full Text] [Related]
8. Challenges facing pathologists evaluating PD-L1 in head & neck squamous cell carcinoma.
Girolami I; Pantanowitz L; Barberis M; Paolino G; Brunelli M; Vigliar E; Munari E; Satturwar S; Troncone G; Eccher A
J Oral Pathol Med; 2021 Oct; 50(9):864-873. PubMed ID: 34157159
[TBL] [Abstract][Full Text] [Related]
9. Programmed death ligand-1 (PD-L1) as a predictive marker for immunotherapy in solid tumours: a guide to immunohistochemistry implementation and interpretation.
Paver EC; Cooper WA; Colebatch AJ; Ferguson PM; Hill SK; Lum T; Shin JS; O'Toole S; Anderson L; Scolyer RA; Gupta R
Pathology; 2021 Feb; 53(2):141-156. PubMed ID: 33388161
[TBL] [Abstract][Full Text] [Related]
10. The prognostic role of PD-L1 expression for survival in head and neck squamous cell carcinoma: A systematic review and meta-analysis.
Yang WF; Wong MCM; Thomson PJ; Li KY; Su YX
Oral Oncol; 2018 Nov; 86():81-90. PubMed ID: 30409325
[TBL] [Abstract][Full Text] [Related]
11. Inter- and intraobserver agreement of programmed death ligand 1 scoring in head and neck squamous cell carcinoma, urothelial carcinoma and breast carcinoma.
Downes MR; Slodkowska E; Katabi N; Jungbluth AA; Xu B
Histopathology; 2020 Jan; 76(2):191-200. PubMed ID: 31243779
[TBL] [Abstract][Full Text] [Related]
12. Evaluating programmed death-ligand 1 (PD-L1) in head and neck squamous cell carcinoma: concordance between the 22C3 PharmDx assay and the SP263 assay on whole sections from a multicentre study.
Cerbelli B; Girolami I; Eccher A; Costarelli L; Taccogna S; Scialpi R; Benevolo M; Lucante T; Luigi Alò P; Stella F; Gemma Pignataro M; Fadda G; Perrone G; D'Amati G; Martini M
Histopathology; 2022 Jan; 80(2):397-406. PubMed ID: 34496080
[TBL] [Abstract][Full Text] [Related]
13. Expression level of PD-L1 is involved in ALDH1A1-mediated poor prognosis in patients with head and neck squamous cell carcinoma.
Zhou AL; Wang X; Yu W; Yang L; Wei F; Sun Q; Wang Y; Kou F; Dong R; Ren X; Zhang X
Pathol Res Pract; 2020 Sep; 216(9):153093. PubMed ID: 32825960
[TBL] [Abstract][Full Text] [Related]
14. The clinicopathological significance of PD-L1 expression assessed by the combined positive score (CPS) in head and neck squamous cell carcinoma.
Wusiman D; Guo L; Huang Z; Li Z; Liu S; Ying J; Li W; An C
Pathol Res Pract; 2022 Aug; 236():153934. PubMed ID: 35691098
[TBL] [Abstract][Full Text] [Related]
15. Frequency of Expression of PD-1 and PD-L1 In Head And Neck Squamous Cell Carcinoma And their Association With Nodal Metastasis: A Cross-Sectional Study.
Malik IS; Asif M; Bashir N; Ara N; Rashid F; Din HU; Malik NS; Bashir A
Asian Pac J Cancer Prev; 2022 Feb; 23(2):467-473. PubMed ID: 35225458
[TBL] [Abstract][Full Text] [Related]
16. Characteristics and impact of programmed death-ligand 1 expression, CD8+ tumor-infiltrating lymphocytes, and p16 status in head and neck squamous cell carcinoma.
Ngamphaiboon N; Chureemas T; Siripoon T; Arsa L; Trachu N; Jiarpinitnun C; Pattaranutaporn P; Sirachainan E; Larbcharoensub N
Med Oncol; 2019 Jan; 36(2):21. PubMed ID: 30666437
[TBL] [Abstract][Full Text] [Related]
17. PD-L1 CPS Scoring Accuracy in Small Biopsies and Aspirate Cell Blocks from Patients with Head and Neck Squamous Cell Carcinoma.
Paintal AS; Brockstein BE
Head Neck Pathol; 2020 Sep; 14(3):657-665. PubMed ID: 31721075
[TBL] [Abstract][Full Text] [Related]
18. Beyond the Percentages of PD-L1-Positive Tumor Cells: Induced Versus Constitutive PD-L1 Expression in Primary and Metastatic Head and Neck Squamous Cell Carcinoma.
Scognamiglio T; Chen YT
Head Neck Pathol; 2018 Jun; 12(2):221-229. PubMed ID: 28948509
[TBL] [Abstract][Full Text] [Related]
19. PD-L1 expression in head and neck carcinoma by combined positive score: a comparison among preoperative biopsy, tumor resection, and lymph node metastasis.
Ambrosini-Spaltro A; Limarzi F; Gaudio M; Calpona S; Meccariello G
Virchows Arch; 2022 Jul; 481(1):93-99. PubMed ID: 35420378
[TBL] [Abstract][Full Text] [Related]
20. PD-1 and PD-L1 expression in HNSCC primary cancer and related lymph node metastasis - impact on clinical outcome.
Schneider S; Kadletz L; Wiebringhaus R; Kenner L; Selzer E; Füreder T; Rajky O; Berghoff AS; Preusser M; Heiduschka G
Histopathology; 2018 Oct; 73(4):573-584. PubMed ID: 29742291
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]